* The 12-week human clinical trial began in early June 2024 and set out to investigate if, through these mechanisms of action, the MindBody GLP-1 System could holistically and sustainably increase GLP-1 hormone levels in overweight adults, without unwanted side effects.* The study was conducted by independent researchers at Lighthouse Research
Those taking semaglutide medications for obesity were seven times more likely to develop the condition
[coverage_gap]
The tool shows: Comparison cards : mechanism, evidence tier, FDA status, weight loss data, dosing, cost, pros, cons, and side effects Bar chart : average weight loss percentage from pivotal clinical trials Radar chart : multi-dimensional comparison across efficacy, evidence quality, convenience, tolerability, cost, and cardiovascular data Emerging research : next-generation compounds including BRP (Stanford's natural peptide), survodutide, orforglipron, and amycretin Understanding the data Each weight-loss figure traces to one specific trial: about 15% for semaglutide (STEP 1), up to 22.5% for tirzepatide (SURMOUNT-1), and 24.2% for retatrutide, only a phase 2 result
In January 2024, the US Food and Drug Administration (FDA) said in a statement that it was evaluating the need for regulatory action on GLP-1 RAs, following reports of suicidal ideation linked to the drugs in the United States
Weekly Tirzepatide injections Regular medical visits & weigh-ins Comprehensive weight loss plan Ongoing support & actionable advice Try Our Weight Loss Tools Calculate your calorie needs, track your progress, and discover which program is right for you
